2015 | AZD9291, a mutant-selective EGFR inhibitor, as first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): Results from a phase 1 expansion cohort. | Ramalingam, Suresh S.; Yang, James Chih-Hsin; Lee, Chee Khoon; Kurata, Takayasu; Kim, Dong-Wan; John, Thomas; Nogami, Naoyuki; Ohe, Yuichiro; Rukazenkov, Yuri; Frewer, Paul; Cantarini, Mireille; Ghiorghiu, Serban; Janne, Pasi A. | J. Clin. Oncol. | | | |
2023 | Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC | Planchard, David; Jänne, Pasi A; Cheng, Ying; CHIH-HSIN YANG ; Yanagitani, Noriko; Kim, Sang-We; Sugawara, Shunichi; Yu, Yan; FAN YUN ; Geater, Sarayut L; Laktionov, Konstantin; Lee, Chee K; Valdiviezo, Natalia; Ahmed, Samreen; Maurel, Jean-Marc; Andrasina, Igor; Goldman, Jonathan; Ghiorghiu, Dana; Rukazenkov, Yuri; Todd, Alex; Kobayashi, Kunihiko | The New England journal of medicine | 23 | | |